Glycogen synthase kinase 3 (GSK-3) is associated with several cellular systems, including immune response.
Lithium, a widely used pharmacological treatment for
bipolar disorder, is a
GSK-3 inhibitor. GSK-3α is the predominant
isoform in human neutrophils. In this study, we examined the effect of
GSK-3 inhibition on the production of TNF-α by neutrophils. In the murine air pouch model of
inflammation,
lithium chloride (LiCl) amplified TNF-α release. In
lipopolysaccharide-stimulated human neutrophils,
GSK-3 inhibitors mimicked the effect of LiCl, each potentiating TNF-α release after 4 h, in a concentration-dependent fashion, by up to a 3-fold increase (ED50 of 1 mM for
lithium). LiCl had no significant effect on cell viability. A positive association was revealed between
GSK-3 inhibition and prolonged activation of the p38/MNK1/
eIF4E pathway of mRNA translation. Using
lysine and
arginine labeled with stable heavy
isotopes followed by quantitative mass spectrometry, we determined that
GSK-3 inhibition markedly increases (by more than 3-fold) de novo TNF-α
protein synthesis. Our findings shed light on a novel mechanism of control of TNF-α expression in neutrophils with
GSK-3 regulating mRNA translation and raise the possibility that
lithium could be having a hitherto unforeseen effect on inflammatory diseases.